Tags

Type your tag names separated by a space and hit enter

Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Cancer Chemother Pharmacol 2014; 74(5):899-909CC

Abstract

PURPOSE

The aim of this retrospective cohort study was to clarify the effect of a branched-chain amino acids (BCAA) on the liver function and the prognosis of Child-Pugh class (C-P) A and B liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) undergoing hepatic arterial infusion chemotherapy (HAIC).

METHODS

Ninety-two adult Japanese patients with LC and aHCC underwent HAIC. They were in C-P A or B, and they showed multiple partial responses or stable disease. We excluded 11 patients classified as C-P C and 47 patients who showed no response. The patients were divided into an HAIC group receiving HAIC alone (n = 43) and a BCAA group treated with HAIC plus BCAA (n = 49). HAIC was delivered via the proper hepatic artery. The BCAA group also received oral administration of BCAA.

RESULTS

In the BCAA group, serum albumin increased significantly after HAIC, while there were no significant changes in serum total bilirubin, serum aminotransferases, prothrombin time, ascites, and hepatic encephalopathy. The C-P score decreased significantly after HAIC compared with before HAIC in C-P B patients, although there was no significant change in C-P A patients. Survival of the BCAA group was significantly longer than that of the HAIC group, with the median survival time being 426 versus 272 days for C-P B patients, although there was no significant difference for C-P A patients.

CONCLUSIONS

Branched-chain amino acids might improve the survival and C-P score by increasing serum albumin in C-P B patients with aHCC receiving HAIC.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Faculty of Medicine, School of Medicine, Toho University, 6-11-1, Omorinishi, Ota-ku, Tokyo, 143-8541, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25138286

Citation

Kanekawa, Takenori, et al. "Importance of Branched-chain Amino Acids in Patients With Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy." Cancer Chemotherapy and Pharmacology, vol. 74, no. 5, 2014, pp. 899-909.
Kanekawa T, Nagai H, Kanayama M, et al. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. Cancer Chemother Pharmacol. 2014;74(5):899-909.
Kanekawa, T., Nagai, H., Kanayama, M., & Sumino, Y. (2014). Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. Cancer Chemotherapy and Pharmacology, 74(5), pp. 899-909. doi:10.1007/s00280-014-2564-z.
Kanekawa T, et al. Importance of Branched-chain Amino Acids in Patients With Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. Cancer Chemother Pharmacol. 2014;74(5):899-909. PubMed PMID: 25138286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. AU - Kanekawa,Takenori, AU - Nagai,Hidenari, AU - Kanayama,Masahiro, AU - Sumino,Yasukiyo, Y1 - 2014/08/20/ PY - 2014/02/10/received PY - 2014/07/07/accepted PY - 2014/8/21/entrez PY - 2014/8/21/pubmed PY - 2015/1/30/medline SP - 899 EP - 909 JF - Cancer chemotherapy and pharmacology JO - Cancer Chemother. Pharmacol. VL - 74 IS - 5 N2 - PURPOSE: The aim of this retrospective cohort study was to clarify the effect of a branched-chain amino acids (BCAA) on the liver function and the prognosis of Child-Pugh class (C-P) A and B liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) undergoing hepatic arterial infusion chemotherapy (HAIC). METHODS: Ninety-two adult Japanese patients with LC and aHCC underwent HAIC. They were in C-P A or B, and they showed multiple partial responses or stable disease. We excluded 11 patients classified as C-P C and 47 patients who showed no response. The patients were divided into an HAIC group receiving HAIC alone (n = 43) and a BCAA group treated with HAIC plus BCAA (n = 49). HAIC was delivered via the proper hepatic artery. The BCAA group also received oral administration of BCAA. RESULTS: In the BCAA group, serum albumin increased significantly after HAIC, while there were no significant changes in serum total bilirubin, serum aminotransferases, prothrombin time, ascites, and hepatic encephalopathy. The C-P score decreased significantly after HAIC compared with before HAIC in C-P B patients, although there was no significant change in C-P A patients. Survival of the BCAA group was significantly longer than that of the HAIC group, with the median survival time being 426 versus 272 days for C-P B patients, although there was no significant difference for C-P A patients. CONCLUSIONS: Branched-chain amino acids might improve the survival and C-P score by increasing serum albumin in C-P B patients with aHCC receiving HAIC. SN - 1432-0843 UR - https://www.unboundmedicine.com/medline/citation/25138286/Importance_of_branched_chain_amino_acids_in_patients_with_liver_cirrhosis_and_advanced_hepatocellular_carcinoma_receiving_hepatic_arterial_infusion_chemotherapy_ L2 - https://dx.doi.org/10.1007/s00280-014-2564-z DB - PRIME DP - Unbound Medicine ER -